Press release
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
Stephen MacMillan to retire from the Board SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and
About this update from Illumina, Inc.
[{"type":"text","content":"Stephen MacMillan to retire from the Board\nSAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Hologic, who joined the Illumina Board in June 2023, has decided to retire from the board in preparation for the company's upcoming annual meeting of shareholders.\n\n\"I'm honored to accept this role at Illumina, a company at the forefront of our rapidly evolving industry, whose groundbreaking innovations continue to transform patient opportunities and shape the field of genomics,\" Dr. Gottlieb said. \"I extend our gratitude to Steve for his dedication and commitment to Illumina, and I look forward to continuing to collaborate with the board and management team to advance the company's mission and to drive profitable growth. We also welcome to the board Keith Meister, who brings experience as an investor in the field of genomics along with a strong record of supporting value creation for shareholders.\"\nMr. MacMillan commented, \"I am pleased with what Illumina has accomplished in advancing genomics and fostering groundbreaking innovations that have shaped our field, and I am grateful to the board for entrusting me with the opportunity to contribute to this remarkable company. I leave with great confidence in the board and the management team. Their collective vision, leadership, and deep commitment to scientific progress give me every reason to believe they'll continue—and indeed amplify—the transformative work we have set in motion.\"\n\"I look forward to working with Illumina's Board and strong management team,\" Mr. Meister said. \"Illumina has the right strategy to drive the expansion of its role in helping to shape the field of genomics and expand the application of these technologies for patient care, and I'm confident in Illumina's ability to accelerate revenue growth and deliver value for shareholders.\"\nAbout Scott Gottlieb, MD\nScott Gottlieb ...